Federal funding BRT recently secured a federal contract with the EPA for mouse assays to assess lead bioavailability, signaling robust government demand for preclinical immunotoxicology and exposure-related studies that can be a lever for expanding relationships with regulatory-focused clients.

NAMs leadership As the first U.S. lab to offer SenzaGen’s GARD in vitro sensitization testing, BRT demonstrates capability in emerging alternative methods, presenting a compelling value proposition to biotech and chemical clients pursuing non-animal testing strategies.

Preclinical focus Specialization in preclinical immunotoxicology, immune safety, and hypersensitivity via in vivo and in vitro assays positions BRT as a niche partner for pharma, biotech, and government programs seeking integrity-heavy data to de-risk product development pipelines.

Growth potential With a small-to-mid-sized team and revenue in the lower-to-mid multi-million range, BRT offers a lean, high-value CRO option for mid- to late-stage programs, potentially appealing to mid-market companies seeking agile partners.

Partnership footprint Active collaboration history with SenzaGen and expanding government work suggests a path to broaden platform offerings (NAMs, immunotoxicology, hypersensitivity) and cross-sell to existing clients in biotech, pharmaceutical, and environmental sectors.